Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 ...
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. | GSK’s antibody-drug conjugate strategy may be making ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies ...
Hosted on MSN
Key human proteins that power coronavirus replication point to new treatment strategies
Despite vaccines and treatments, SARS-CoV-2—the virus that causes COVID-19—continues to pose a global health threat, driven by new variants and its ability to hijack human cells in ways that still ...
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback